Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.19.6 extracted from

  • Lazcano, I.; Uribe, R.M.; Martinez-Chavez, E.; Vargas, M.A.; Matziari, M.; Joseph-Bravo, P.; Charli, J.L.
    Pyroglutamyl peptidase II inhibition enhances the analeptic effect of thyrotropin-releasing hormone in the rat medial septum (2012), J. Pharmacol. Exp. Ther., 342, 222-231.
    View publication on PubMed

Inhibitors

Inhibitors Comment Organism Structure
Glp-PSI[P(O)(OH)CH2]-His-Pro-NH2
-
Rattus norvegicus
p-Glu-Asn-Pro-7-amido-4-methylcoumarin
-
Rattus norvegicus

Organism

Organism UniProt Comment Textmining
Rattus norvegicus Q10836
-
-

Source Tissue

Source Tissue Comment Organism Textmining
medial septum 12 to 14% of cell profiles express pyroglutamyl peptidase II mRNA in the medial septum-diagonal band of Broca, in this region the specific activity of the enzyme is relatively high. Injection of the pyroglutamyl peptidase II inhibitor p-Glu-Asn-Pro-7-amido-4-methylcoumarin into the medial septum enhances the effect of thyrotropin-releasing hormone. The injection of a phosphinic thyrotropin-releasing hormone analog, a higher affinity inhibitor of pyroglutamyl peptidase II, diminishes the duration of ethanol-induced loss of righting reflex by itself Rattus norvegicus
-

General Information

General Information Comment Organism
physiological function in the medial septum pyroglutamyl peptidase II activity may limit thyrotropin-releasing hormone action, presumably by reducing the concentration of thyrotropin-releasing hormone in the extracellular fluid around cells coexpressing pyroglutamyl peptidase II and thyrotropin-releasing hormone-receptor 1 Rattus norvegicus